JAK2-V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia

International Journal of Hematology-Oncology and Stem Cell Research

Bahram Chahardouli¹  Babak Bahar¹  SA Mousavi¹  Kamran Alimoghaddam¹  SH Ghaffari¹  Ardeshir Ghavamzadeh¹  Fatemeh Nadali²  Sh Ferdowsi³  P Karimzadeh³  H Dargahi³  N Einollahi³ 

[1] Hematology-Oncology and BMT Research Center, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran;Pathology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran;School of Allied Health Sciences, Tehran University of Medical Sciences, Tehran, Iran;

关键词: JAK2V617F mutation;    BCR-ABL translocation;    ASO-PCR;    ARMS-PCR;   

DOI  :  

来源: DOAJ

【 摘 要 】

JAK2 is a tyrosine kinase that plays an important role in the signaling pathways of many hematopoietic growth factor receptors. A single acquired point mutation – V617F – in JAK2 occurs in the great majority of patients with polycythemia vera (PV) and approximately half of the patients with idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET). In contrast, the JAK2-V617F mutation is only rarely found in chronic myeloid leukemia (CML) but, recently, some authors have reported the coexistence of JAK2V617F and BCR/ABL+ in CML patients expressing the p210 BCR–ABL oncoprotein. Here, we report a CML patient with the expression of p210/b2a2 type BCR–ABL transcript and JAK2V617F mutation.

【 授权许可】

Unknown